Last reviewed · How we verify
Intensive BP treatment group
This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients.
This is a treatment strategy that uses intensive blood pressure control to reduce cardiovascular events and mortality in hypertensive patients. Used for Hypertension with cardiovascular disease or high cardiovascular risk.
At a glance
| Generic name | Intensive BP treatment group |
|---|---|
| Also known as | Control of SBP to <120 mmHg |
| Sponsor | China National Center for Cardiovascular Diseases |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The 'Intensive BP treatment group' refers to a clinical trial arm comparing aggressive blood pressure lowering (typically systolic <120 mmHg) versus standard control (typically <140 mmHg) in patients with hypertension and cardiovascular risk factors. The mechanism relies on the principle that lower blood pressure targets reduce vascular damage, atherosclerosis progression, and subsequent cardiovascular complications.
Approved indications
- Hypertension with cardiovascular disease or high cardiovascular risk
Common side effects
- Hypotension/dizziness
- Acute kidney injury
- Syncope
Key clinical trials
- Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2) (PHASE3)
- International Care Bundle Evaluation in Cerebral Hemorrhage Research (PHASE4)
- A Study of Blood Pressure Control During Cancer Treatment (PHASE2)
- Intensive Postpartum Antihypertensive Treatment (PHASE3)
- Optimised Treatment for Hypertension Trial (NA)
- Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial) (PHASE2)
- Arterial Stiffness and Blood Pressure (NA)
- Intensive Ambulance-delivered Blood Pressure Reduction in Hyper-Acute Stroke Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: